Previous 10 | Next 10 |
2023-05-26 14:59:36 ET Verastem ( NASDAQ: VSTM ) climbed ~131% on Friday after announcing that 45% of patients with ovarian cancer who received the experimental therapy avutometinib as part of a combination regimen in a Phase 2 trial indicated a decrease in tumor size. The R...
2023-05-26 13:41:10 ET Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liquidity. So outside of all other risks involved, liquidity risk presents a significant hurdle. For those unfamiliar,...
Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer Clinically Meaningful Response Rates and Manageable Safety and Tolerability Profile Continue to be Demonstrated in Heavily Pretreated Patient Population ...
2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...
2023-05-19 16:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Karin Tollefson to its Board of Directors, effective May 15, 2023. Dr. Tollefson is the Senior Vice President and Head of Global Medical A...
2023-05-09 23:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-05-09 17:29:27 ET Verastem press release ( NASDAQ: VSTM ): Q1 Non-GAAP EPS of -$0.09. Verastem Oncology ended the first quarter of 2023 with cash, cash equivalents and investments of $111.2 million. Shares -4% AH. For further details see: Verastem No...
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) to be Presented at the American Society of Clinical Oncology Annual Meeting Studies of Avutometinib Combinations ...
2023-04-30 07:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...